The present invention relates to removal of hemoglobin from a sample. In particular the present invention relates to a method in which a protein with specificity towards hemoglobin and/or the complex of hemoglobin with haptoglobin is immobilized on a solid support and utilized to remove hemoglobin from a sample comprising hemoglobin, such as a hemolysed sample obtained from a subject.

A sorbent based monitoring system for measuring the solute concentration of at least one component of a fluid. The system has a sorbent regeneration system for regeneration of the fluid and has a sorbent cartridge that has at least one material layer. The fluid is conveyed through the sorbent cartridge and contacts at least one sensor after having contacted at least one material layer.

The invention relates to an apparatus for extracorporeal removal of protein-bound toxins from blood plasma comprising a first line device, a second line device, a third line device and a fourth line device, a dialyzer or hemofilter arranged between the first line device and the second line device and/or an adsorber, means for generating a field, at least partially surrounding the first line device and/or the dialyzer or hemofilter and/or the adsorber, a controllable fluid conveyance device arranged in the first line device and/or the second line device, and at least one controllable body fluid conveyance unit arranged in the third line device and/or the fourth line device, a filter, wherein the permeate side of the filter is connected to the first line device and the second line device, and the side of the filter to be dialyzed is connected at its inlet to the third line device, which can be connected to a patient and is connected at its outlet to the fourth line device which can be connected to the patient, wherein a controllable flow of fluid through the line devices and the dialyzer or hemofilter and/or the adsorber can be generated by means of the fluid conveyance devices.

The present invention concerns an extracorporeal circuit for regional scoagulation of blood comprising a line for taking the blood from the patient, a first filtering unit, and a line for returning the blood to the patient defining a main circuit, the extracorporeal circuit comprising a secondary circuit for recirculation of the plasma water comprising: a calcium removal assembly adapted to provide a solution with low calcium content in said main circuit;
the extracorporeal circuit further comprising: first means for the infusion of said solution with low calcium content into said main circuit upstream of said first filtering unit and of said calcium removal assembly with respect to the blood flow direction in the main circuit and second means for the infusion of an electrolytic re-establishment solution located downstream of said first means with respect to the direction of the blood flow in said main circuit.

The present specification is directed to systems, apparatus and methods for prophylactically preventing, or for treating the onset and/or progression of Cerebral Amyloid Angiopathy (CAA), acute stroke conditions, or Alzheimer's disease. The progression of, stabilizing, or improving symptoms related to these conditions are treated by monitoring a pathophysiological change indicative of the conditions in a patient, based on the monitoring, determining if amyloid plaque is present in a perivascular space of the patient, optionally determining an extent of amyloid plaque in the perivascular space, and based on the presence of amyloid plaque in the perivascular space of the patient, determining a treatment protocol for the patient. The treatment protocol includes administering to the patient a high density lipoprotein composition derived from mixing a blood fraction with a lipid removing agent.

Despite therapeutic advances in the field of oncology, treatment toxicity, drug resistance, and inadequate tumor site delivery restrict the benefit of cancer chemotherapy regimens. Disclosed are extracorporeal devices comprising adsorbent components that are suitable for treating a subject prior to and following administration of a dose of a chemotherapy drug, wherein the devices are configured to remove circulating factors comprising a chemotherapy drug from blood or plasma. Also disclosed herein are methods of reducing the bloodstream presence of circulating factors that mediate drug resistance, drug toxicity, and cancer metastasis, wherein circulating factors include without limitation, tumor-derived and/or chemotherapy-induced extracellular vesicles or exosomes.

A blood processing system includes a collection line for carrying blood, a blood separation device for separating the blood into first and second fractions, a plasma delivery line for delivering the first blood fraction to an adsorption device, and a peristaltic pump. The adsorption device adsorbs plasma of the first blood fraction. Portions of the collection and plasma delivery lines are positioned in a channel of the peristaltic pump, and the peristaltic pump causes the blood to flow through the collection line at a first flow rate and causes the first blood fraction to flow through the plasma delivery line at a second flow rate that is less than the first flow rate. In some implementations, the collection and plasma delivery lines are tubes having different internal diameters facilitating such differential flow rates. In some implementations, the peristaltic pump is the only pump in the blood processing system.

The present disclosure is directed to methods of removing proteins, including cytokines, from blood and blood products, the methods comprising contacting the blood or blood product with a form of carbon having high graphitic contents and slit-shaped mesopores and macropores, the pore size dimensions chosen to be comparable to the size of the proteins, wherein the contacting results in the removal of high levels of the protein from the blood or blood product in minutes or hours.

A combined bio-artificial liver support system, includes branch tubes that are connected in sequence: a blood input branch tube, an upstream tail end, a first plasma separation branch tube comprising at least a first plasma separator, a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber, a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly, and a plasma return branch tube, a downstream tail end of which is set as a blood output end.

Provided herein are bedside systems and methods for performing customized cell-based therapies and treatments in a patient-connected, closed-loop continuous-flow manner, including cellular modifications and treatments, e.g., to produce chimeric antigen receptor-T (CAR-T) cells among other cellular modifications and treatments.